Medicinal Chemistry Unit 5 ReviewMajor Drug Classes in Medicinal Chemistry

Key Concepts and Terminology

• Pharmacodynamics studies how drugs interact with target molecules in the body and produce pharmacological effects
• Pharmacokinetics examines how the body processes drugs through absorption, distribution, metabolism, and excretion (ADME)
• Bioavailability measures the fraction of an administered drug that reaches systemic circulation unchanged
• Half-life represents the time required for the concentration of a drug in the body to decrease by half
• Therapeutic index compares the amount of a drug that causes therapeutic effects to the amount that causes toxicity
  • A higher therapeutic index indicates a safer drug with a larger difference between therapeutic and toxic doses
• Receptor binding involves the interaction between a drug molecule and its specific target receptor protein
• Agonists are drugs that bind to receptors and activate them, mimicking the effects of endogenous ligands (acetylcholine)
• Antagonists bind to receptors but do not activate them, blocking the effects of endogenous ligands or agonists (naloxone)

Major Drug Classes Overview

• Analgesics relieve pain by acting on the nervous system or peripheral pain mechanisms (opioids, NSAIDs)
• Antimicrobials treat infections caused by bacteria, viruses, fungi, or parasites (antibiotics, antivirals, antifungals)
  • Antibiotics specifically target bacterial infections and can be broad-spectrum or narrow-spectrum (penicillins, cephalosporins)
• Cardiovascular drugs manage conditions related to the heart and blood vessels (antihypertensives, anticoagulants)
• Central nervous system (CNS) drugs act on the brain and spinal cord to treat neurological and psychiatric disorders (antidepressants, antipsychotics)
• Endocrine system drugs regulate hormonal imbalances or treat hormone-related diseases (insulin, thyroid hormones)
• Chemotherapeutic agents are used to treat cancer by targeting rapidly dividing cells or specific molecular pathways (cisplatin, targeted therapies)
• Immunomodulators modify the immune system's response, either suppressing or enhancing its activity (corticosteroids, monoclonal antibodies)

Pharmacological Mechanisms

• Receptor agonism occurs when a drug binds to and activates a receptor, triggering downstream signaling pathways
• Receptor antagonism involves a drug binding to a receptor without activating it, preventing the binding of endogenous ligands or agonists
• Enzyme inhibition reduces the activity of target enzymes, disrupting specific biochemical processes (ACE inhibitors)
  • Competitive inhibitors compete with the substrate for the active site of the enzyme
  • Non-competitive inhibitors bind to allosteric sites, altering the enzyme's conformation and reducing its activity
• Ion channel modulation alters the function of ion channels, influencing the flow of ions across cell membranes (calcium channel blockers)
• Transporter inhibition blocks the activity of transporters responsible for the uptake or efflux of specific molecules (serotonin reuptake inhibitors)
• Receptor desensitization occurs when prolonged exposure to an agonist reduces the receptor's responsiveness over time (beta-2 adrenergic receptor desensitization)
• Enzyme induction increases the synthesis of target enzymes, leading to enhanced metabolic activity (cytochrome P450 induction)

Structure-Activity Relationships

• Chemical structure determines a drug's physicochemical properties, target interactions, and pharmacological effects
• Functional groups are specific arrangements of atoms within a molecule that confer distinct chemical properties and reactivity
  • Substitution of functional groups can alter a drug's potency, selectivity, or pharmacokinetic properties
• Stereochemistry refers to the three-dimensional arrangement of atoms in a molecule, which can significantly impact drug-target interactions
  • Enantiomers are mirror-image molecules that can exhibit different pharmacological profiles (R-thalidomide, S-thalidomide)
• Bioisosteres are functional groups or substructures that can be substituted while retaining similar biological activity
• Quantitative structure-activity relationship (QSAR) models mathematically relate chemical structure to biological activity, guiding drug optimization
• Pharmacophores are the essential structural features of a drug molecule responsible for its pharmacological activity
• Homology modeling predicts the three-dimensional structure of a target protein based on its amino acid sequence and known structures of related proteins

Drug Design and Development

• Target identification involves selecting a specific molecular target (receptor, enzyme) associated with a disease or condition
• High-throughput screening (HTS) rapidly assesses large compound libraries for activity against a chosen target
• Lead optimization improves the potency, selectivity, and pharmacokinetic properties of lead compounds through iterative chemical modifications
• In vitro testing evaluates drug candidates in cell-based or biochemical assays to assess their efficacy and safety
• In vivo testing assesses drug candidates in animal models to determine their pharmacological effects, toxicity, and pharmacokinetic properties
  • Preclinical studies are conducted in animals to establish safety and efficacy before human trials
• Clinical trials are conducted in human volunteers to evaluate the safety, efficacy, and optimal dosing of drug candidates
  • Phase 1 trials assess safety and pharmacokinetics in a small group of healthy volunteers
  • Phase 2 trials evaluate efficacy and side effects in a larger group of patients with the target condition
  • Phase 3 trials are large-scale studies that confirm efficacy and safety in a broader patient population
• Regulatory approval is required before a drug can be marketed, based on the results of preclinical and clinical studies

Therapeutic Applications

• Hypertension is treated with antihypertensive drugs that lower blood pressure through various mechanisms (ACE inhibitors, beta-blockers)
• Diabetes mellitus is managed with insulin or oral hypoglycemic agents that regulate blood glucose levels (metformin, sulfonylureas)
• Depression is treated with antidepressants that modulate neurotransmitter systems in the brain (SSRIs, SNRIs)
  • Selective serotonin reuptake inhibitors (SSRIs) increase serotonin levels by blocking its reuptake (fluoxetine)
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs) block the reuptake of both serotonin and norepinephrine (venlafaxine)
• Infectious diseases are treated with antimicrobial agents that target specific pathogens (antibiotics for bacterial infections, antivirals for viral infections)
• Cancer is treated with chemotherapeutic agents that target rapidly dividing cells or specific molecular pathways involved in tumor growth (cisplatin, targeted therapies)
• Asthma is managed with bronchodilators that relax airway smooth muscle and corticosteroids that reduce inflammation (albuterol, fluticasone)
• Alzheimer's disease is treated with cholinesterase inhibitors that increase acetylcholine levels in the brain (donepezil)

Side Effects and Safety Considerations

• Adverse drug reactions (ADRs) are unintended and harmful effects that occur at normal therapeutic doses
  • Type A reactions are dose-dependent and predictable based on the drug's pharmacology (anticholinergic effects of tricyclic antidepressants)
  • Type B reactions are idiosyncratic and not related to the drug's pharmacology (penicillin allergies)
• Drug-drug interactions occur when one drug alters the pharmacokinetics or pharmacodynamics of another drug (CYP450 inhibition)
• Contraindications are conditions or factors that preclude the use of a drug due to an unacceptably high risk of adverse effects (pregnancy, certain medical conditions)
• Therapeutic drug monitoring (TDM) involves measuring drug concentrations in the blood to optimize dosing and minimize toxicity (lithium, vancomycin)
• Pharmacogenomics studies how genetic variations influence an individual's response to drugs, guiding personalized therapy
• Teratogenicity refers to a drug's potential to cause birth defects when administered during pregnancy (thalidomide)
• Black box warnings are the strictest labeling requirements for drugs with serious or life-threatening risks (antidepressants, anticoagulants)

Emerging Trends and Future Directions

• Precision medicine aims to tailor drug therapy based on an individual's genetic profile, disease subtype, or other specific factors
• Targeted drug delivery systems aim to selectively deliver drugs to specific tissues or cells, minimizing off-target effects (antibody-drug conjugates)
• Nanotechnology involves the use of nanoscale materials and devices for drug delivery, diagnosis, and imaging (liposomes, polymeric nanoparticles)
• Biologics are drugs derived from living organisms or their products, including proteins, antibodies, and nucleic acids (monoclonal antibodies, gene therapies)
  • Monoclonal antibodies are engineered antibodies that target specific antigens, used for cancer treatment and autoimmune disorders (rituximab, adalimumab)
• Combination therapies involve the use of multiple drugs with different mechanisms of action to achieve synergistic effects or overcome drug resistance (HIV treatment)
• Drug repurposing identifies new therapeutic applications for existing drugs, reducing the time and cost of drug development (sildenafil)
• Artificial intelligence (AI) and machine learning (ML) are being applied to various aspects of drug discovery and development, from target identification to clinical trial design
• Organ-on-a-chip technologies are microfluidic devices that mimic the structure and function of human organs, providing more predictive models for drug testing